Vastra Tradgardsgatan 15
Stockholm 111 53
Sweden
46 86 15 20 40
https://www.oncopeptides.com/sv
Settore/i:
Settore:
Impiegati a tempo pieno: 57
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Jakob Lindberg Med. Lic | Chief Scientific Officer | 7,26M | N/D | 1972 |
Ms. Sofia Heigis M.Sc. | Chief Executive Officer | N/D | N/D | 1980 |
Prof. Rolf Larsson M.D., Ph.D. | Founder | N/D | N/D | N/D |
Prof. Rolf Lewensohn M.D., Ph.D. | Founder | N/D | N/D | N/D |
Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. | Founder | N/D | N/D | N/D |
Dr. Kristina Luthman Ph.D. | Founder | N/D | N/D | N/D |
Prof. Hans Ehrsson M.D. | Founder | N/D | N/D | N/D |
Mr. Peter Nygren | Founder | N/D | N/D | 1959 |
Mr. Henrik Bergentoft | Chief Financial Officer | N/D | N/D | 1974 |
Ms. Eva Nordström M.Sc., MSc Pharm | COO & Deputy MD | N/D | N/D | 1970 |
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
L'ISS Governance QualityScore di Oncopeptides AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.